Study summary
Rituximab and cyclophosphamide with steroids worked about equally well
0.85risk ratio for remission at 12 months (not significant)
What was tested
A pooled analysis of randomized and cohort studies comparing rituximab with cyclophosphamide plus steroids for moderate- or high-risk primary membranous nephropathy.
What they found
- Remission at 12 months was similar (risk ratio 0.85, not significant).
- Side effects and serious side effects were similar.
What it means
Both remain standard options; rituximab is often preferred because it avoids cyclophosphamide toxicity.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.